INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated – INSM

(NASDAQ:INSM), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insmed and certain of its officers and/or directors have engaged […]

AIQ introduces direct-to-menu media, closing the gap between cannabis advertising and purchase

DETROIT, Jan. 13, 2026 (GLOBE NEWSWIRE) — Alpine IQ (AIQ), the leading data and marketing platform for cannabis retailers and brands, today announced a major evolution of its Loops media product: direct-to-menu destination URLs that route every brand impression to the appropriate retailer's menu, brand page, or product page. This update enables brands to reach

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics – NKTR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics – NKTR GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at

OVBC ANNOUNCES CASH DIVIDEND

On Tuesday Jan. 13, 2026, Ohio Valley Banc Corp. [Nasdaq: OVBC] Board of Directors declared a cash dividend of $0.23 per common share payable on Feb. 10, 2026, to shareholders of record as of the close of business on Jan. 23, 2026. “The start of the new year comes with both challenges and the anticipation

Hallador Energy Company Announces Proposed Public Offering of Common Stock

Hallador Energy Company Announces Proposed Public Offering of Common Stock GlobeNewswire January 13, 2026 TERRE HAUTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) — Hallador Energy Company (Nasdaq: HNRG), today announced that it intends to offer and sell $50 million of shares of its common stock in an underwritten public offering. All of the shares to

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated – INSM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated – INSM GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at

AIQ introduces direct-to-menu media, closing the gap between cannabis advertising and purchase

AIQ introduces direct-to-menu media, closing the gap between cannabis advertising and purchase GlobeNewswire January 13, 2026 DETROIT, Jan. 13, 2026 (GLOBE NEWSWIRE) — Alpine IQ (AIQ), the leading data and marketing platform for cannabis retailers and brands, today announced a major evolution of its Loops media product: direct-to-menu destination URLs that route every brand impression

FirstEnergy to Webcast Fourth Quarter Earnings Teleconference

FirstEnergy Corp. (NYSE: FE) will release financial results for the fourth quarter and full year of 2025 after markets close on Tuesday, Feb. 17. These results will be discussed by FirstEnergy management during a conference call with financial analysts at 9 a.m. EST on Wednesday, Feb. 18. A question-and-answer session will follow. Investors, customers and

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

(NASDAQ:TGTX), Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectively Full Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK,

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones GlobeNewswire January 13, 2026 Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million,

Scroll to Top